SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure after Q3 results highlighted weaker trading activity, with headline profit largely driven by gains on crypto holdings; the Binance hack and broader crypto weakness added to selling pressure. Traders are split between viewing the decline as a buying opportunity and worrying that soft volumes and shaken confidence in exchanges could prolong the downturn.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians quarterly results beat expectations and the company raised its full-year delivery outlook as the R2 ramp gained traction, driving bullish discussion about improving execution and future growth. Traders remain divided, with some expecting a recovery while others point to continued cash burn and a muted share-price reaction.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Bank of America upgrade, citing DraftKings Predictions exchange as a potential growth opportunity, has fueled rebound interest after a steep selloff. Traders remain divided over whether rising exchange activity can offset regulatory uncertainty, competition from Kalshi and Polymarket, and pressure on the sportsbook business.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 AML trial reaching its 80-event milestone, which starts database lock, unblinding and final analysis, is drawing attention ahead of the expected topline results. Bulls point to the trials long duration and extended GPS dosing as possible signs of durable survival benefit, while skeptics question the dosing changes and trial design; the share-price decline has added to the debate.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

Biotechs sector-wide swings and rotation are driving attention, with traders weighing weakness tied to rising-rate concerns and money moving between biotech and tech against hopes for renewed inflows and M&A. The debate is whether the pullback is a deeper correction or a buying opportunity, with XBIs support levels and upcoming biotech catalysts in focus.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Cornings quarterly earnings beat and upbeat outlook, driven by AI-related optical communications demand, are being weighed against a sharp share-price pullback and bearish chart signals. Traders are split between viewing the decline as an overreaction to strong results and pointing to put-heavy options activity and broken support as signs of further near-term pressure.

Select Sector SPDR Trust (The) - State Street Consumer Staples Select Sector SPDR ETF

Consumer Staples Select Sector SPDR Fund

XLP is drawing attention as investors rotate toward defensive consumer staples amid weakness in technology and AI-related stocks, with traders highlighting the funds rebound toward record highs. The rally has prompted bullish technical commentary, while others caution that staples look stretched and the defensive trade may be crowded.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a 52-week high has focused attention on TGTX, with traders weighing BRIUMVIs sales momentum and Q3 results against anticipated subcutaneous BRIUMVI data. Buyout speculation and possible short covering are also prominent, but no acquisition is confirmed.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,715,255,345.65554501 with 589,238,256,711,817.89342663 in circulation. The last known price of Shiba Inu is 0.00000467 USD and is down -2.68 over the last 24 hours. It is currently trading on 1123 active market(s) with $35,462,996.64 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIB is drawing attention for choppy, largely range-bound trading, with repeated technical-chart posts describing consolidation and traders debating whether it can break resistance or resume falling. Long-term holders are buying dips and hoping for a meme-coin rally, while skeptics cite weak utility, token burns that have not shifted sentiment, and prolonged underperformance.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is under pressure amid a broader crypto and AI data-center selloff, with traders especially focused on its reliance on CoreWeave as Helioss tenant and the lack of a new tenant announcement. Some see the strong quarterly results, buyback authorization, and data-center growth as support, while others worry about customer concentration, financing risks, and management credibility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2026, and provided recent corporate...

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate...

Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?

Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced the presentation of initial data from the randomized Phase 2 trial (Duravelo-2) evaluating...

Bicycle Therapeutics (NASDAQ:BCYC) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen cut shares of Bicycle Therapeutics from a 'hold' rating to a 'sell' rating in a research report on Saturday...

Bicycle Therapeutics (NASDAQ:BCYC) Announces Earnings Results, Misses Estimates By $0.25 EPS

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts...

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell re...

Bicycle Therapeutics (BCYC) to Release Quarterly Earnings on Thursday

Bicycle Therapeutics (NASDAQ:BCYC) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at...

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

$BCYC Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.15 up 82.35% YoY
• Reported revenue of $34.06M up 190.37% YoY
• Bicycle Therapeutics reported cash and cash equivalents of $469.9M as of September 30, 2026, with expected cash runway into 2030, as stated in quarterly results.

Stocktwits

Bicycle Therapeutics Plc - ADR

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.15 up 82.35% YoY
• Reported revenue of $34.06M up 190.37% YoY
• Bicycle Therapeutics reported cash and cash equivalents of $469.9M as of September 30, 2026, with expected cash runway into 2030, as stated in quarterly results.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.15 up 82.35% YoY
• Reported revenue of $34.06M up 190.37% YoY
• Bicycle Therapeutics reported cash and cash equivalents of $469.9M as of September 30, 2026, with expected cash runway into 2030, as stated in quarterly results.

Bicycle Therapeutics reported cash and cash equivalents of $469.9M versus $628.1M, deprioritized zelenectide pevedotin for internal development, and disclosed the risk that clinical trials may have unsatisfactory outcomes as of September 30, 2026.

Bicycle Therapeutics received FDA Orphan Drug Designation for nuzefatide in pancreatic cancer, is actively enrolling a Phase 2 trial, and expects first company-sponsored BT1702 radioligand trial initiation in 2H 2027.

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.66
Prev Close	$3.82
Open	$3.75
Dividend Yield	0.00%
50-Day Moving Average	$3.83
Beta	1.24
Avg. Volume	441,390.22
PE Ratio	-1.34

52-Week High	$8.11
52-Week Low	$3.33
Market Capitalization	$184.38M
EPS (Annual)	-$3.17
Price to Book	0.50
Revenue Per Employee	$252,623.69

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCYC Fundamentals